CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity
CELL
Authors: Wang, Chao; Yosef, Nir; Gaublomme, Jellert; Wu, Chuan; Lee, Youjin; Clish, Clary B.; Kaminski, Jim; Xiao, Sheng; Horste, Gerd Meyer Zu; Pawlak, Mathias; Kishi, Yasuhiro; Joller, Nicole; Karwacz, Katarzyna; Zhu, Chen; Ordovas-Montanes, Maria; Madi, Asaf; Wortman, Ivo; Miyazaki, Toru; Sobel, Raymond A.; Park, Hongkun; Regev, Aviv; Kuchroo, Vijay K.
Abstract
Th17 cells play a critical role in host defense against extracellular pathogens and tissue homeostasis but can induce autoimmunity. The mechanisms implicated in balancing "pathogenic" and "non-pathogenic" Th17 cell states remain largely unknown. We used single-cell RNA-seq to identify CD5L/AIM as a regulator expressed in non-pathogenic, but not in pathogenic Th17 cells. Although CD5L does not affect Th17 differentiation, it is a functional switch that regulates the pathogenicity of Th17 cells. Loss of CD5L converts non-pathogenic Th17 cells into pathogenic cells that induce autoimmunity. CD5L mediates this effect by modulating the intracellular lipidome, altering fatty acid composition and restricting cholesterol biosynthesis and, thus, ligand availability for Rorgt, the master transcription factor of Th17 cells. Our study identifies CD5L as a critical regulator of the Th17 cell functional state and highlights the importance of lipid metabolism in balancing immune protection and disease induced by T cells.
Therapeutic Targeting of Apoptosis Inhibitor of Macrophage/CD5L in Sepsis
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
Authors: Gao, Xun; Yan, Xingxing; Yin, Yibing; Lin, Xue; Zhang, Qun; Xia, Yun; Cao, Ju
Abstract
The factors involved in disturbing host homeostasis during sepsis are largely unknown. We sought to determine the immunopathological role of apoptosis inhibitor of macrophage (AIM)/CD5L in sepsis. Here, we show that blockade of AIM led to significantly increased survival after experimental sepsis, and it decreased local and systemic inflammation, reduced tissue injury, and inhibited bacterial dissemination in the blood, in particular at later time points. Supplementation of recombinant AIM in sepsis resulted in increased tissue injury, amplified inflammation, increased bacteremia, and worsened mortality. Interestingly, the most important difference in the production of cytokines and chemokines after in vivo AIM blockade or AIM administration during sepsis was IL-10. In vitro, AIM enhanced IL-10 production from macrophages, neutrophils, or lymphocytes. In vivo, the beneficial effects of AIM blockade and the detrimental effects of AIM addition on experimental sepsis were ablated by treatment with recombinant IL-10 and neutralizing anti-IL-10 antibodies, respectively. This study is the first to identify AIM as an important mediator in disturbing host homeostasis in sepsis.